MedTrace Logo

SLNB After Nipple Sparing Mastectomy

NCT04140188 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-10-29

No results posted yet for this study

Summary

Sentinel Lymph Node Biopsy (SLNB) after nipple sparing mastectomy (NSM) is controversial. This study aims to investigate feasibility of SLNB with radioisotope method.

Conditions

  • Sentinel Lymph Node Biopsy
  • Mastectomy, Subcutaneous

Interventions

DIAGNOSTIC_TEST

Senti-Scint (99mTc- pertechnetate combined with human albumin)

Senti-Scint will be injected via intradermal route to the breast with history of previous NSM.

Sponsors & Collaborators

  • Acibadem University

    lead OTHER

Principal Investigators

  • Halil KARA · Acibadem University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-11-30
Primary Completion
2020-04-30
Completion
2020-06-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04140188 on ClinicalTrials.gov